ARGX:EURONEXT BRUSSELSargenx SE Analysis

ARGX is trading at $915, comfortably above its 20‑day, 50‑day and 200‑day moving averages, with a bullish MACD crossover and an RSI of 57 indicating modest upward momentum. The stock is riding an "Extreme Greed" sentiment (Fear‑Greed Index 91) and sits near a strong support level at $838 while still having room to the 52‑week high of $954. Volatility remains elevated at over 40% for the past month, but the beta of roughly 0.5 suggests the share price is less sensitive to broader market swings. Recent positive Phase III data for efgartigimod in myositis and Sjögren’s disease adds a catalytic catalyst, reinforcing the bullish technical picture.
Fundamentally, ARGX delivered 62% revenue growth to $4.74 bn, with gross margins of 58% and operating margins above 30%, underscoring a high‑margin business model. The company boasts a cash pile of $4.44 bn against minimal debt, providing ample runway for its expanding autoimmune pipeline. Although the current PE of 40× exceeds the biotech peer average of 29×, the forward PE of 24.8× and analyst consensus (median target $1,042) imply a potential upside of roughly 15%. The consensus recommendation remains a "Buy," reflecting confidence in both the near‑term trial momentum and the longer‑term growth trajectory.